A reduction of HbAs1c after 3 months predicts 2-year responsiveness to sitagliptin treatment

Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai, Hiroshi Itoh

Research output: Contribution to journalArticle

3 Citations (Scopus)


Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of

Original languageEnglish
Pages (from-to)2981-2989
Number of pages9
JournalInternal Medicine
Issue number23
Publication statusPublished - 2015 Dec 1



  • Diabetes
  • Dipeptidyl peptidase-4 inhibitor
  • Glycemic control
  • HbA1c
  • Hemoglobin
  • Sitagliptin

ASJC Scopus subject areas

  • Internal Medicine

Cite this